Clinical Trials Details

RMC-6236-401: Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib

Summary

The aim of this expanded access program is to make daraxonrasib available to eligible patients with pancreatic adenocarcinoma, a serious and life-threatening condition, who have no comparable or satisfactory alternative therapy approved by the FDA.